240 Structures of mycobacterial glycosyltransferases define a binding site for an anti-tuberculosis drug.

239 An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells.

238 Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite.

237 Elesclomol therapy stops the progression of neurodegeneration and improves survival in a mouse model of Menkes disease.

236 An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.

235 An open-source drug discovery platform enables ultra-large virtual screens.

234 A dual effect of ursolic acid to the treatment of multiple sclerosis through both immunomodulation and direct remyelination.

233 A scorpion-derived peptide-steroid conjugate accumulates in cartilage and reverses inflammation in a rat model of arthritis without steroid toxicity.

232 AB569, a nontoxic chemical tandem that kills major human pathogenic bacteria.

231 JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.

230 Antitumor astins originate from the fungal endophyte Cyanodermella asteris living within the medicinal plant Aster tataricus.

229 Chimeric peptidomimetic antibiotics against Gram-negative bacteria.

228 A new antibiotic selectively kills Gram-negative pathogens.

227 A multistep biocatalytic cascade is applied to the synthesis of the experimental HIV drug islatravir.

226 A small molecule protects mitochondrial integrity by inhibiting mTOR activity.

225 A rat, dog, and human Liver-Chip designed using microengineered Organs-on-Chips technology recapitulates species-specific drug toxicities.

224 Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice.

223 Hidden antibiotics in actinomycetes can be identified by inactivation of gene clusters for common antibiotics.

222 Clinical benefit was observed in 34% of a cohort of 215 patients with cancer who received treatment with anticancer drugs outside of their approved label, in the Drug Rediscovery protocol trial.

221 Repurposing dasatinib for diffuse large B cell lymphoma.

Free Images for Presentation: sunipix SUNIPIX